Molecular mechanisms mediating anti-myeloma activity of proteasome inhibitor PS-341.

被引：0

作者：

Hideshima, T ^{[1
]}

Mitsiades, C ^{[1
]}

Akiyama, M ^{[1
]}

Hayashi, T ^{[1
]}

Chauhan, D ^{[1
]}

Richardson, PG ^{[1
]}

Schlossman, RL ^{[1
]}

Podar, K ^{[1
]}

Munshi, NC ^{[1
]}

Mitsiades, N ^{[1
]}

Anderson, KC ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA

来源：

BLOOD | 2002年 / 100卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3215

引用

页码：814A / 814A

页数：1

共 50 条

[41] The oral proteasome inhibitor ONX 0912 has bone anabolic effects in addition to anti-myeloma effects
Hurchla, Michelle A.
Hornick, Mary C.
Li, Aixiao
Collins, Lynne
Kirk, Christopher J.
Piwnica-Worms, David
Vij, Ravi
Tomasson, Michael H.
Weilbaecher, Katherine N.
CANCER RESEARCH, 2011, 71
[42] Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model
LeBlanc, R
Catley, LP
Hideshima, T
Lentzsch, S
Mitsiades, CS
Mitsiades, N
Neuberg, D
Goloubeva, O
Pien, CS
Adams, J
Gupta, D
Richardson, PG
Munshi, NC
Anderson, KC
CANCER RESEARCH, 2002, 62 (17) : 4996 - 5000
[43] Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells
Chauhan, D
Li, GL
Podar, K
Hideshima, T
Mitsiades, C
Schlossman, R
Munshi, N
Richardson, P
Cotter, FE
Anderson, KC
BLOOD, 2004, 104 (08) : 2458 - 2466
[44] A novel HSP70 inhibitor demonstrates potent anti-myeloma activity
Bailey, Charvann K.
Budina, Anna
Murphy, Maureen
Nefedova, Yulia
CANCER RESEARCH, 2015, 75
[45] BAY 43-9006, a dual raf kinase/VEGF receptor inhibitor, has significant in vitro activity in myeloma and synergizes with the proteasome inhibitor PS341.
Kumar, S
Timm, M
Haug, J
Kimlinger, T
Kline, M
Rajkumar, SV
Adjei, A
CLINICAL CANCER RESEARCH, 2005, 11 (24) : 8989S - 8989S
[46] Glutamine-Dependence Targeting By Asparaginase Significantly Increases Anti-Myeloma Activity of Proteasome Inhibitors
Minetto, Paola
Soncini, Debora
Cagnetta, Antonia
Guolo, Fabio
Retali, Veronica
Rivoli, Giulia
Bisso, Nadia
Di Felice, Nikki
Miglino, Maurizio
Canepa, Letizia
Lemoli, Roberto Massimo
Gobbi, Marco
Cea, Michele
BLOOD, 2017, 130
[47] A Novel Bruton's Tyrosine Kinase Inhibitor CC-292 In Combination With The Proteasome Inhibitor Carfilzomib Iimpacts Multiple Myeloma Bone Microenviroment With Resultant Anti-Myeloma Activity
Eda, Homare
Santo, Loredana
Cirstea, Diana D.
Yee, Andrew J.
Scullen, Tyler A.
Nemani, Neeharika
Mishima, Yuko
Arastu-Kapur, Shirin
Evans, Erica
Singh, Juswinder
Kirk, Christopher J.
Westlin, William F.
Raje, Noopur S.
BLOOD, 2013, 122 (21)
[48] Proteasome inhibitor PS-341 and docetaxel: sequence of administration may be crucial
Garfield, D
LANCET ONCOLOGY, 2001, 2 (12): : 714 - 714
[49] Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer
Adams, J
CURRENT OPINION IN CHEMICAL BIOLOGY, 2002, 6 (04) : 493 - 500
[50] Investigative cardiovascular study of the proteasome inhibitor PS-341 in the mouse.
Rottman, J
Csizmadia, V
Ozkaynak, E
Kadambi, V
Ganley, K
Cardoza, K
Juedes, M
Bouchard, P
TOXICOLOGICAL SCIENCES, 2003, 72 : 47 - 47

← 1 2 3 4 5 →